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delivery systems for improving the bioavailability of an 
existing drug molecule. Eye drops are the most preferred 
method of administering drugs to the eye. Although 
topical and localized applications are still an acceptable and 
preferred route for ocular drug delivery, such dosage forms 
are no longer sufficient to combat ocular diseases such as 
glaucoma as they have poor bioavailability, which is the 
result of the efficient mechanisms protecting the eye from 
harmful materials and agents. Such protective mechanisms 
include reflex blinking, lacrimation, tear turnover, 
and drainage of tear, all of which results in the rapid 
removal of the drug from the eye surface. Also frequent 
instillation of concentrated medication is required at the 
INTRODUCTION
Vesicular drug delivery system using colloidal particulate 
carriers (liposomes or niosomes) have distinct advantages 
over conventional dosage forms because colloidal particles 
can act as drug containing reservoirs. Modification of the 
particle composition or surface can adjust the affinity for 
the target site and/or the drug release rate. The slow drug 
release from the carrier system may reduce the toxicity of 
the drug and hence these carriers play an important role 
in drug delivery.[1] The primary objective of creating new 
drug delivery system in ocular therapeutics is to improve 
existing ocular dosage forms and exploit newer drug 
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The objective of the present investigation was to design a vesicular formulation of brimonidine tartrate and 
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of nano-vesicles sustained for a longer period of time. Stability studies revealed that the vesicle formulations 
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convenient for patients.
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site of action and this is inconvenient for the patient.[2]
The development of various vesicular drug delivery 
systems allows the entrapment of the drug molecule into 
a lipid bilayer or in surfactant vesicles and thus allows us to 
increase drug concentration at the site of application and, 
thus, to improve bioavailability. Such vesicles (liposomes 
and niosomes) act as carriers for controlled ocular drug 
delivery by preventing metabolism of the drug by enzymes 
present at the corneal epithelial surface. Vesicle-entrapped 
drug can be easily administered in liquid dosage forms such 
as eye drops with good patient compliance, modulated drug 
release profile and high drug pay-load. Brimonidine tartrate 
is an α2-adrenergic receptor agonist. It acts by decreasing 
synthesis of aqueous humor, as well as by increasing its 
drainage from the eye. As a treatment for glaucoma, it is 
usually given in a 0.2% w/v (2 mg/mL) eye drop form that 
has to be administered 2-3 times daily. In humans, after 
topical dosing, the mean apparent half-life of brimonidine 
tartrate in the systemic circulation is approximately 3 h. 
The plasma protein binding of brimonidine tartrate after 
topical dosing in humans is approximately 29%. The major 
part of the dose (around 75% of the dose) is excreted 
within 5 days as metabolites in urine. The drug is used 
to treat open-angle glaucoma or ocular hypertension and 
is also used to induce miosis in people suffering from 
poor night vision after Lasik or PRK surgery.[3-5] In the 
present study, to produce a sustained effect of the drug, 
an attempt was made to develop a vesicular drug delivery 
system (liposomes and niosomes) of brimonidine tartrate 
for ocular administration. We investigated its intraocular 
pressure (IOP) lowering activity and its other physical 
properties and the drug release pattern.
MATERIALS AND METHODS
Materials
Brimonidine tartrate was obtained from FDC Aurangabad, 
India, as a gift sample. Cholesterol, soya lecithin, and span-60 
were obtained from CDH Laboratories, New Delhi. Diethyl 
ether, chloroform, alcohol, alpha-tocopherol, potassium 
dihydrogen phosphate, and disodium hydrogen phosphate 
were obtained from E-Merck India Ltd, Mumbai. DPPC 
(1, 2–Dipalmitoyl-sn-glycero-3-phosphocholine) was 
obtained as a gift sample from Genzyme Pharmaceuticals, 
Switzerland.
Preparation of vesicles
In the present study, three formulations each of liposomes 
and niosomes, of brimonidine tartrate were prepared 
by film hydration method.[6] All the lipid components 
(including surfactant Span-60, for niosomes) of the 
formulation (as per the formula given in Table 1) were taken 
in a round-bottom flask and dissolved in sufficient quantity 
(10 mL) of organic solvent (chloroform). The organic 
solvent was evaporated using a rotary flash evaporator 
under reduced pressure at a temperature of about 60°C till 
a lipid film was formed inside the flask. The dried lipid film 
obtained was hydrated with aqueous phase of phosphate 
buffer (pH 7.4, 10 mL) containing the drug. The flask was 
shaken for 1 h to get liposomal or niosomal formulations. It 
was allowed to equilibrate at room temperature. Liposomal 
formulations were named as LF1, LF2, and LF3, and the 
niosomal formulations were named NF1, NF2 and NF3. 
The stable colloidal suspension was then sonicated for two 
cycles. During the first cycle, the suspension was sonicated 
at 80% amplitude with a pulse of 0.5 cycles per second for 
a period of 3 min, followed by 3 min rest (excess heat may 
be generated during probe sonication, which may damage 
the lipids). After 3 min, the second cycle was processed 
for 3 min at 80% amplitude with 0.5 cycles per sec pulse 
for another 3 min. The size of the vesicles was analyzed 
by Nano Zeta-sizer (Malvern, Instruments Ltd, USA) after 
sonication.
Determination of size and shape
Particle size, and the polydispersity index of the vesicles 
were determined using Malvern Zeta sizer.
Entrapment efficiency
Entrapment efficiency of brimonidine tartrate in the 
vesicles was determined as follows: After sonication, 
1 mL of the vesicle suspension was taken in a 1 mL 
microcentrifuge tube, and centrifuged at 20,000 rpm for 
1 h at 4ºC in a cold centrifuge to get a white pellet. To the 
pellet, 500 µL of 0.1 N NaOH (the drug is highly soluble 
in 0.1N NaOH) was added and vortexed thoroughly for 3 
min to get a white suspension. To this, 5 mL methanol was 
added to get a clear solution. This was further vortexed for 
2 min to ensure that the vesicles were lysed completely to 












LF 1 1:1:1 6.5 32.34
LF 2 1:1:2 6.7 39.78
LF 3 1:1:3 7.2 42.43
NF1 1:1:1 6.7 32.00
NF2 1:1:2 7.2 41.20
NF 3 1:1:3 7.4 43.20Prabhu, et al. J Young Pharm. 2010;2(4): 356-361
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release the drug.[7] This solution (1 mL) was further diluted 
with methanol and the absorbance was determined using 
a Shimadzu UV/VIS spectrophotometer.
The entrapment efficiency (EE) was calculated using the 
following formula: 
Percentage entrapment  
(%EE) = 
Entrapped drug  
(mg/mL) 
× 100 Total drug added 
(mg/mL)
In vitro drug release study
In vitro drug release study for formulations of vesicles was 
studied by membrane diffusion technique.[8] The diffusion 
medium was 19 mL of freshly prepared glutathione 
bicarbonated ringer (GBR) equilibrated at 37±0.5°C 
temperature. The pH of the medium was maintained at 
7.2-7.4 by passing CO2. This medium closely resembles 
simulated tear fluid (STF). The samples were analyzed 
spectrophotometrically for concentration of brimonidine 
tartrate at 320 nm. The experimental data was subjected 
to statistical analysis using one-way ANOVA. P< 0.05, was 
considered statistically significant. 
Ex- in vitro drug release study
Ex-in vitro drug release study for prepared vesicular 
formulations was studied by the method described above. 
In this study, porcine cornea was used as the diffusion 
membrane. All the procedures followed were similar to 
that explained under in vitro drug release study. 
In vivo intraocular pressure lowering activity
In vivo IOP lowering activity of vesicular preparations of 
brimonidine tartrate was studied in normotensive male 
albino rabbits weighing 1.2-2.5 kg. The animals were housed 
under well controlled conditions of temperature (22±2°C), 
and humidity (55±5%), with a 2/12-h light-dark cycle, and 
free access to food and water. The rabbits were divided into 
three groups containing 6 rabbits each (6 each for marketed 
product, niosomes, and liposomesrespectively). Group 1, 
was treated with marketed formulation (Alphagan® eye 
drops, 0.02%), group 2, was treated with liposomes, and 
group 3, was treated with niosomes. The protocol of the 
experiment was approved by the Institutional Animal 
Ethics Committee (K.S. Hegde Medical Academy, Reg. No 
115/1999/CPCSEA). 
To induce acute glaucoma, 5% dextrose solution (15 
mL/kg) was intravenously infused through the marginal 
ear vein. The basal intraocular pressure was measured 
by with tonometere. The drug formulations (20 µL) 
were administered to the rabbits 30 min before the 
administration of dextrose solution. The IOP changes were 
recorded every 30 min, till the pressure difference between 
the control eye and treated eye was found to be zero. The 
formulation was instilled on to the corneal surface of one 
eye, and with the contra-lateral eye being the control. IOP 
was measured by the tonometry method with the help of 
a Schiotz tonometere. All IOP measurements were carried 
out by the same operator, and using same tonometere. Each 
rabbit was given a washout period of 3 days after every 
treatment. The ocular hypotensive activity was expressed 
as the average difference in IOP between the treated and 
control eye of the same rabbit, according to the equation 
∆ IOP = IOP of treated eye — IOP of control eye.[8,9] 
The experimental data was subjected to statistical analysis, 
using one-way ANOVA. P< 0.05, was considered to be 
statistically significant. 
Stability study
In the present work, a stability study was carried out for 
selected formulations LF3 and NF3. They were stored at 
room temperature and under refrigeration (2-8°C), for 8 
weeks, and the formulations were then evaluated for the 
drug content and shape of the vesicles.
Determination of drug release kinetics
To know the mechanism of drug release from these 
formulations, the data were treated according to first-order 
(log cumulative percentage of drug remaining vs time), 
Higuchi’s (cumulative percentage of drug released vs square 
root of time), and zero-order (cumulative amount of drug 
released vs time) pattern.[10]
RESULTS AND DISCUSSION
Vesicular formulations were prepared using the film 
hydration method and were characterized [Table 1]. The 
average size of the vesicles ranged from 6.50 µ-7.40 µ, 
before sonication and all the vesicles were found to be 
spherical in shape and multilamellar [Figures 1 and 2]. 
The sonication resulted in much smaller vesicles, which 
is essential if irritation to the eye is to be avoided. The 
size of particles in ophthalmic dosage forms, apart from 
influencing bioavailability, plays an important role in its 
irritation potential; hence, it is recommended that particles 
of ophthalmic solution be less than 10 µ so as to minimize 
irritation to the eye.[8] The size of sonicated vesicles was 
found to be in the range of 210-245 nm. The amount of 
drug entrapped in vesicles ranged between 32% and 42% 
w/w [Table 1]. Preparation and evaluation of nano-vesicles of brimonidine tartrate
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The comparison of the in vitro drug release profiles of pure 
drug solution and for each formulation is summarized in 
Table 2. It was observed that pure drug solution released 
approximately 75% of drug within 2 h, while vesicle 
formulations LF3 and NF3 showed 18% and 22% drug 
release respectively in 8 h. Liposomes showed marginal 
increment in drug release with increase in the lipid 
composition, i.e., at drug: cholesterol: DPCC ratio of 1:1:3, 
the release was found to be faster compared to that at the 
ratio of 1:1:1 (22.15% vs 18.12%). The release of drug from 
niosomes was found to be significantly (P>.05) different 
from that of liposomes. For example NF1 released 24% of 
drug compared to 18% of LF1. The result of in vitro drug 
release profiles of the formulations showed that vesicular 
formulations provides the more prolonged release of drug 
when compared to pure drug solution. 
The comparative ex-in vitro drug release profile for pure 
drug solution and vesicular formulations is summarized 
in Table 3. The in vitro and ex-in vitro release models did 
not show any significant difference in drug release due 
to the effect of the diffusion membrane. The prolonged 
Table 2: Comparative in-vitro dissolution profile of different formulations
Time (h) Percentage amount of drug release 
Pure drug solution Formulation 
NF1 NF2 NF3 LF1 LF2 LF3
1 68.00 ± 1.4 06.43 ± 0.79 10.69 ± 0.99 14.13 ± 0.99 03.26 ± 0.45 04.46 ± 0.99 05.81 ± 0.99
2 77.40 ± 1.2 13.67 ± 0.68 19.29 ± 0.98 22.35 ± 1.09 10.86 ± 0.37 12.86 ± 0.98 12.75 ± 0.98
3 78.80 ± 1.3 16.43 ± 0.93 20.28 ± 0.97 24.91 ± 1.16 13.42 ± 0.56 14.40 ± 0.99 13.76 ± 1.00
4 78.30 ± 1.2 17.18 ± 0.77 21.42 ± 0.94 26.52 ± 0.98 14.38 ± 0.91 14.58 ± 0.98 16.55 ± 1.10
5 80.00 ± 1.3 21.64 ± 0.94 22.69 ± 0.99 27.99 ± 0.98 15.67 ± 0.35 16.67 ± 0.97 19.05 ± 0.99
6 79.64 ± 1.4 22.13 ± 0.95 23.19 ± 0.98 29.30 ± 0.99 16.23 ± 0.45 16.83 ± 0.98 19.40 ± 0.98
7 81.54 ± 1.6 23.58 ± 0.87 24.19 ± 0.99 31.11 ± 0.97 16.92 ± 1.12 16.98 ± 1.00 21.11 ± 0.99
8 83.42 ± 1.1 24.12 ± 1.12 27.19 ± 1.05 33.85 ± 0.98 18.12 ± 1.23 18.92 ± 1.10 22.51 ± 0.98
Table 3: Comparative ex-in vitro dissolution profile of different formulations
Time (h) Percentage amount of drug release 
Pure drug solution Formulation 
NF1 NF2 NF3 LF1 LF2 LF3
1 67.56± 1.60 07.89 ± 0.99 06.37 ± 0.99 12.89 ± 0.99 6.81± 0.89 7.89 ± 0.99 05.37 ± 0.93
2 78.31± 1.10 13.04 ± 0.98 13.12 ± 0.98 15.68 ± 0.98 12.12 ± 0.45 13.04 ± 0.98 11.13 ± 0.93
3 78.80± 1.40 13.36 ± 0.99 14.31 ± 1.09 18.92 ± 0.97 13.17 ± 0.67 13.36 ± 0.99 13.21 ± 1.10
4 78.98± 1.30 14.00 ± 0.98 15.87 ± 1.17 24.76 ± 0.94 13.98 ± 0.28 14.00 ± 0.98 14.87 ± 0.98
5 80.00± 1.30 15.64 ± 0.97 16.59 ± 0.99 27.56 ± 0.99 14.69 ± 0.57 15.64 ± 0.97 15.52 ± 0.56
6 80.64± 1.25 17.56 ± 0.99 18.57 ± 0.98 27.89 ± 0.98 16.34 ± 0.78 17.56 ± 0.99 17.53 ± 0.98
7 81.74± 1.80 17.76 ± 1.05 20.55 ± 0.99 28.56 ± 0.99 17.26 ± 0.98 17.76 ± 1.00 19.38 ± 0.78
8 83.12± 1.30 18.89 ± 1.10 22.56 ± 0.98 29.81 ± 1.07 18.39 ± 1.05 18.89 ± 1.10 21.54 ± 0.98
Figure 1: Photomicrograph of liposomes before sonication Figure 2: Photomicrograph of niosomes before sonicationPrabhu, et al. J Young Pharm. 2010;2(4): 356-361
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release rate may be attributed largely to the drug transport 
by a diffusion controlled mechanism from vesicles. The 
in vitro and ex-in vitro drug release studies showed that, 
there was slow and prolonged release of drug from all the 
formulations following zero-order kinetics.
To study the in vivo performance of prepared formulations, 
IOP lowering activity was determined. It was found that 
with vesicular formulations IOP lowering activity was 
sustained for longer periods (3-4 h). The marketed product 
showed activity within 30 min, but the activity not sustained 
beyond 60 min. It was found that the IOP difference 
produced between pure drug solution and vesicles is very 
significant (P> 0.05). Vesicular formulations sustained 
the action for a prolonged period of time (240 min)   
[Figure 3]. The IOP-lowering activity of pure drug solution 
did not sustain long. It was also observed that at the end 
of 240 min, the effect of all the formulations was found 
to be nil. This may have been because rise in IOP induced 
by injection of 5% dextrose solution does not last long. 
Nevertheless, the experimental data proves the sustained 
action of vesicular formulation in comparison to marketed 
eye drops. The better reduction in IOP with vesicles may 
probably be due to the better partitioning of drug between 
vesicle and eye corneal surface. Also, the release of drug 
from vesicles increases the concentration at the corneal 
surface, and thus longer contact time of vesicles at the 
corneal surface, leads to higher bioavailability of drug. 
Thus, the vesicles act as a drug carrier, and change the rate 
and extent of absorption, resulting in reduction of IOP 
for more prolonged periods.
The time to onset of action, duration of action, percentage 
IOP-lowering activity, and peak effective time were also 
measured. The maximum IOP (IOP of contra-lateral eye, 
30.4 mmHg) was recorded between 1.5-2.5 h and this 
was considered as 100% glaucoma induction. During the 
same period, the reduction in IOP observed in eye treated 
with formulation considered as percentage reduction in 
IOP. The marketed formulation produced the maximum 
percentage reduction of 59% between 1.0-1.5 h. The 
vesicles showed a maximum of 39% reduction in IOP 
between 2-2.5 h. Though, a higher percentage reduction 
of IOP was observed with the marketed product,the effect 
was not sustained. In comparison, vesicular formulations 
produced a IOP-lowering action that was sustained longer 
duration of time (3.5-4 h), [Table 4].
The result of the stability study showed satisfactory 
and acceptable stability with the vesicles stored at 
temperatures of (2-8°C). However, liposomes stored at 
room temperature showed sign of drug leak and structural 
deformation, niosomes stored at room temperature 
showed acceptable stability, with no change in shape and 
no significant difference in drug content.
CONCLUSION
The in vitro and ex-in vitro drug release studies showed 
sustained release zero-order kinetics. The in vivo IOP-
lowering activity of vesicular formulations was found to 
be significant and sustained, which is promisimg for its 
physiological effectiveness. Thus, vesicular systems have 
the potential to meet the need for an ophthalmic drug 
delivery system that not only has the convenience of a 
drop formulation, but, can also localize and maintain drug 
activity at the site for a long period of time. This would 
help to reduce the frequency of drug administration and 
thereby improve patient compliance.
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Table 4: Change in IOP-lowering activity parameters













0.5± 0.2 1.5± 0.2 0.5± 0.4 59
LF3 0.5± 0.4 1.1± 0.3 3.0± 0.5 39
NF3 0.5± 0.2 1.8± 0.2 4.0± 0.9 39
Figure 3: Comparative IOP-lowering activity. -Δ-Niosomal formulation. 
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